Indication
Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with mild to moderate alpha-mannosidosis.
Medicine details
- Medicine name:
- velmanase alfa (Lamzede)
- SMC ID:
- SMC2466
- Pharmaceutical company
- Chiesi Limited
- BNF chapter
- Nutrition and blood
- Submission type
- Ultra-orphan initial assessment
- Publication due date:
- 12 September 2022
- SMC meeting date:
- 02 August 2022
- Patient group submission deadline:
- 04 July 2022